BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

InVasc Therapeutics Announces Financing of $3.15 Million and Board Changes


7/9/2010 7:10:14 AM

ATLANTA--(BUSINESS WIRE)--InVasc Therapeutics, Inc. today has had an initial closing of $3,150,000 in its first institutional financing. The investment was led by Trois I Investments Industriels Internationaux S.A., headquartered in Luxembourg.

“We welcome Trois I and our other investors,” stated William Johnston, Ph.D., Chief Executive Officer of InVasc. “The funds raised will primarily be used to advance a Phase II trial for INV-144. The members of our new board will include Daniele Cardoso of Trois I, Larry Dillaha, the former EVP and Chief Medical Officer of Sciele Pharma, Bill Schaeffer, Chief Operating Officer of InVasc and me.”

About InVasc

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks associated with cardiometabolic diseases. Cardiovascular and metabolic diseases such as diabetes, hypertension, stroke and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND later this year for INV-144 targeting the slowing of the progression of chronic kidney disease in hypertensive diabetic patients. In a human clinical trial, INV-141, a sister compound, demonstrated statistical significance in the reduction of proteinuria in the same patient population. InVasc’s pipeline development is supported by two recent SBIR grants.

This is not an offering of securities. The securities sold or to be sold have not and will not be registered under the Securities Act of 1933 and will not be offered or sold absent registration under the Securities Act of 1933 or an applicable exemption from the registration requirements of the Securities Act of 1933.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES